US drug launch prices reach $257,000 median amid access barriers

A joint report from the Institute for Clinical and Economic Review and West Health found that the median net price of newly launched prescription drugs in the United States reached $257,000 per year in 2025, an inflation-adjusted increase of 35% from $190,000 in 2022. The median declined slightly, by 2%, between 2024 and 2025, but remained at historically high levels. The analysis focused on “net price,” meaning the price paid after rebates and discounts, rather than the publicly advertised list price, which may not reflect the amount ultimately paid.

The report’s pricing estimates concern annual net prices for drugs included in the analysis and describe the launch-year market rather than the subsequent evolution of each product’s price. About one in four drugs introduced in 2025 had an annual net price exceeding $500,000. A further 34% were launched at prices between $200,000 and $500,000. Taken together, those categories show that more than half of the 2025 launches in the report had annual net prices of at least $200,000, while a substantial minority exceeded half a million dollars per year.

ICER also compared launch prices with its recommended price benchmarks for newly approved drugs that the institute had previously reviewed. In that subset, only about one-third of the medicines were priced at or below the relevant benchmark; the remainder exceeded ICER’s estimated value. This comparison applied only to drugs for which ICER had completed a review and established a benchmark. It did not demonstrate that price differences caused lower use, poorer adherence or worse clinical outcomes, and the release did not provide a count of the medicines in this subset.

Patient access was also assessed during the first year after approval. Among the outpatient prescriptions examined, only one-third were ultimately filled within 30 days of a patient attempting to fill them. A significant proportion of prescriptions were rejected because the medicine was not covered, with new-to-market coverage blocks identified as a likely contributor. The finding therefore describes the early post-approval experience for the outpatient prescriptions included in the analysis, rather than every prescription written, filled or experienced by patients during that period.

The report’s leaders characterized high launch prices and uneven access as major barriers across the US health system. Sarah K. Emond, president and CEO of ICER, said that overpayment for drugs beyond their value to patients is contributing to decreased access and called for fair pricing to be paired with fair access. Timothy Lash, president and chair of the West Health Policy Center, said many Americans were struggling to obtain needed prescription medicines and that higher prices can force difficult tradeoffs for seniors living on fixed incomes. These statements represented the organizations’ interpretation of the report’s findings and policy priorities.

Medicare beneficiaries experienced higher rates of coverage rejection than patients covered by other payer types, according to the report’s access findings. Lash said this pattern made the burden of high launch prices especially stark for Medicare recipients, noting that beneficiaries who did obtain access could still face higher costs. Because the analysis covered the first year after approval and included both filled and rejected outpatient prescriptions, the results offer a view of early access after a drug’s launch. They do not represent a count of all patients who eventually received treatment.

Separate survey findings released with the report showed widespread concern about affordability. In July 2026, nearly 40% of Americans surveyed by the West Health-Gallup Center for Healthcare said they were concerned or very concerned that their household would be unable to pay for needed prescription drugs during the following 12 months. That share was up from 25% in July 2022. Concern was also more pronounced among respondents with multiple health conditions: 49% of people with three or more chronic conditions expressed concern or very concern, compared with 36% of adults aged 65 and older.

The launch-price analysis followed a protocol ICER announced in May 2026. ICER identified IPD Analytics and IQVIA as data partners and collaborated with the National Health Council on patient engagement. The report deliberately centered net prices because earlier drug-pricing analyses had often concentrated on public list prices, which do not always equal the price paid after rebates and discounts. Its access component added a prescription-level view by tracking whether attempts to obtain outpatient medicines succeeded within 30 days after launch, including the role of coverage rejections.

The available release does not detail the number of drugs represented in every pricing category or the number of outpatient prescriptions examined in the access analysis. Its scope also centers on selected US launches, the comparison of medicines previously reviewed by ICER, and access during the first year after approval. As a result, the findings should not be treated as a direct measurement of every segment of the US drug market or as evidence about long-term patient outcomes. They instead show how the median real net launch price changed over the reported period, how prices were distributed among recent launches, and how often the outpatient prescriptions studied were filled promptly or rejected because of lack of coverage.

ICER scheduled a public webinar for October 27, 2026, at noon Eastern Time to discuss rising launch prices and their implications for affordability and access. Foluso Agboola, senior vice president of research at ICER, was to present the report’s main findings before a panel discussion moderated by Emond. The announced panel included Rebecca Kirch of the National Patient Advocate Foundation, Magda Rusinowski of the Business Group on Health, and Namrata Kaur Uberoi of West Health. Taken together, the report found that the median net launch price reached $257,000 in 2025, many launches carried annual prices in the hundreds of thousands of dollars, only about one-third of newly approved medicines previously reviewed by ICER met its recommended price benchmark, and just one-third of the outpatient prescriptions studied were filled within 30 days of the initial attempt.

Subject of Research: US prescription drug launch prices and early outpatient access

Article Title: ICER, West Health releases new report indicating that median prices of newly launched drugs continue to exceed $250,000

Article References: ICER, West Health releases new report indicating that median prices of newly launched drugs continue to exceed $250,000. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: drug launch prices, net prices, prescription drugs, patient access, coverage rejections, Medicare, health affordability, ICER, West Health, prescription fulfillment, West, Health